Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock and Warrants
-
Shares outstanding
-
27,467,750
-
Total 13F shares
-
19,415,909
-
Share change
-
+176,002
-
Total reported value
-
$41,730,123
-
Price per share
-
$2.15
-
Number of holders
-
45
-
Value change
-
+$373,518
-
Number of buys
-
7
-
Number of sells
-
2
Institutional Holders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) as of Q2 2024
As of 30 Jun 2024,
AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,415,909 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Octagon Capital Advisors LP, Frazier Life Sciences Management, L.P., TCG Crossover Management, LLC, CITADEL ADVISORS LLC, JANUS HENDERSON GROUP PLC, VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., and BlackRock Inc..
This page lists
45
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.